Related content

Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin’s lymphoma in a developing country?

By Ruiz-Delgado Guillermo J   Gómez-Almaguer David   Tarín-Arzaga Luz C   Cantú-Rodriguez Olga G   Urdaneta Carlos Alarcón   Rodríguez-Morales Uxmal   Calderón-Garcia Jackeline   Fernández-Vargas Omar   Montes-Montiel Maryel   Sánchez-Cárdenas Mónica   Ruiz-Argüelles Guillermo J  

Hematology, Vol. 17, Iss. 4, 2012-07 ,pp. : 193-197

Maney Publishing

Access to resources Recommend Favorite

Tandem myeloablative ¹³¹I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients

By Deshayes Emmanuel   Kraeber-Bodéré Françoise   Vuillez Jean-Philippe   Bardiès Manuel   Teulon Isabelle   Pouget Jean-Pierre  

Immunotherapy, Vol. 5, Iss. 12, 2013-12 ,pp. : 1283-1286

Future Medicine

Access to resources Recommend Favorite

High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma

By Chen Ming-Huang  

Annals of Hematology, Vol. 87, Iss. 6, 2008-06 ,pp. : 475-480

Springer Publishing Company

Access to resources Recommend Favorite

Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation

By Lee Ming-Yang  

Annals of Hematology, Vol. 87, Iss. 4, 2008-04 ,pp. : 285-289

Springer Publishing Company

Access to resources Recommend Favorite

Tri-lineage disease involving sideroblastic anaemia, multiple myeloma and B-cell non-Hodgkin's lymphoma in the same patient

By Ianotto Jean-Christophe  

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 273-274

Springer Publishing Company

Access to resources Recommend Favorite